2011
A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C
Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, Mulligan DC, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinkhabwala M, Koneru B, Abecassis M, Millis M, Jennings LW, Fasola CG. A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transplantation 2011, 17: 1394-1403. PMID: 21850690, DOI: 10.1002/lt.22417.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAntibodies, Monoclonal, HumanizedAntiviral AgentsBiopsyChi-Square DistributionDaclizumabDrug Therapy, CombinationFemaleGraft RejectionHepacivirusHepatitis C, ChronicHumansImmunoglobulin GImmunosuppressive AgentsKaplan-Meier EstimateLiver FailureLiver TransplantationMaleMiddle AgedMycophenolic AcidProportional Hazards ModelsProspective StudiesRecurrenceRisk AssessmentRisk FactorsRNA, ViralSurvival RateTacrolimusTime FactorsTreatment OutcomeUnited StatesConceptsAcute cellular rejectionSteroid-free immunosuppressionLiver transplant recipientsHCV recurrenceMycophenolate mofetilTransplant recipientsHCV RNA-positive subjectsHepatitis C virus infectionSevere HCV recurrenceSteroid-free groupC virus infectionChronic hepatitis CGraft survival ratesProportion of patientsLiver biopsy samplesCellular rejectionChronic HCVStandard immunosuppressionSteroid sparingHepatitis CLess diabetesMulticenter trialMulticenter studyPatient survivalArm 1
2006
Living donor liver transplantation for hepatitis C‐related cirrhosis: No difference in histological recurrence when compared to deceased donor liver transplantation recipients
Guo L, Orrego M, Rodriguez‐Luna H, Balan V, Byrne T, Chopra K, Douglas DD, Harrison E, Moss A, Reddy KS, Williams JW, Rakela J, Mulligan D, Vargas HE. Living donor liver transplantation for hepatitis C‐related cirrhosis: No difference in histological recurrence when compared to deceased donor liver transplantation recipients. Liver Transplantation 2006, 12: 560-565. PMID: 16555313, DOI: 10.1002/lt.20660.Peer-Reviewed Original ResearchConceptsDeceased donor liver transplantationDonor liver transplantationLiver transplantationHistological recurrenceHepatitis CDeceased-donor liver transplantation (DDLT) recipientsEnd-stage liver disease (MELD) scoreDonor liver transplantation recipientsHepatitis C virus infectionKaplan-Meier survival analysisDetectable HCV RNAHistological recurrence rateC virus infectionGraft survival ratesLiver Disease scoreActivity of inflammationLiver transplantation recipientsStatistical differenceChild-TurcotteDDLT groupLDLT patientsPugh scoreRecurrent HCVLiver transplantYears posttransplantation
2004
Hepatitis C Virus Quasi-Species Dynamics Predict Progression of Fibrosis after Liver Transplantation
Arenas JI, Gallegos-Orozco JF, Laskus T, Wilkinson J, Khatib A, Fasola C, Adair D, Radkowski M, Kibler KV, Nowicki M, Douglas D, Williams J, Netto G, Mulligan D, Klintmalm G, Rakela J, Vargas HE. Hepatitis C Virus Quasi-Species Dynamics Predict Progression of Fibrosis after Liver Transplantation. The Journal Of Infectious Diseases 2004, 189: 2037-2046. PMID: 15143471, DOI: 10.1086/386338.Peer-Reviewed Original ResearchMeSH Keywords5' Untranslated RegionsDisease ProgressionElectrophoresis, Polyacrylamide GelFemaleGenetic VariationHepacivirusHepatitis C, ChronicHumansLiver CirrhosisLiver TransplantationMaleMiddle AgedPhylogenyPolymorphism, Single-Stranded ConformationalReverse Transcriptase Polymerase Chain ReactionRNA, ViralViral Envelope ProteinsConceptsOrthotopic liver transplantationHepatitis C virusLiver transplantationGroup 1Quasi speciesSeverity of recurrenceGroup 1 patientsGroup 2 patientsE2 regionProgression of fibrosisPost-OLT periodCourse of infectionHeteroduplex mobility assayHCV complexityHCV infectionC virusGroup 2PatientsTransplantationSingle-strand conformational polymorphismLiver samplesInfectionWeeksQuasi-species dynamicsYearsHepatitis C Virus Recurrence in Living Donor Liver Transplant Recipients
Rodriguez-Luna H, Vargas HE, Sharma P, Ortiz J, De Petris G, Balan V, Byrne T, Moss A, Mulligan D, Rakela J, Douglas DD. Hepatitis C Virus Recurrence in Living Donor Liver Transplant Recipients. Digestive Diseases And Sciences 2004, 49: 38-41. PMID: 14992432, DOI: 10.1023/b:ddas.0000011599.78222.9e.Peer-Reviewed Original ResearchConceptsDeceased donor transplantationHepatitis C virusLiver transplantationLDLT groupDonor liver transplant recipientsHepatitis C virus recurrenceEnd-stage liver diseaseHCV RNA titersLiver transplant populationLiver transplant recipientsIncidence of rejectionHistological recurrenceChronic hepatitisTransplant recipientsVirus recurrenceDonor transplantationTransplant populationHCV PCRLiver biopsyLiver diseaseAggressive recurrenceSingle pathologistC virusRNA titersInstitutional protocolTreatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon &agr;2b and ribavirin: an open-label series1
Rodriguez-Luna H, Khatib A, Sharma P, De Petris G, Williams JW, Ortiz J, Hansen K, Mulligan D, Moss A, Douglas DD, Balan V, Rakela J, Vargas HE. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon &agr;2b and ribavirin: an open-label series1. Transplantation 2004, 77: 190-194. PMID: 14742979, DOI: 10.1097/01.tp.0000100481.14514.bb.Peer-Reviewed Original ResearchMeSH KeywordsAntiviral AgentsDrug Therapy, CombinationFemaleHepacivirusHepatitis CHumansImmunosuppressive AgentsInterferon alpha-2Interferon-alphaLiver Function TestsLiver TransplantationMaleMiddle AgedPolyethylene GlycolsRecombinant ProteinsRecurrenceReverse Transcriptase Polymerase Chain ReactionRibavirinRNA, ViralTime FactorsTreatment OutcomeConceptsOrthotopic liver transplantationEnd of treatmentHCV recurrenceLiver transplantationPEG-IFNHepatitis C virus recurrenceRecurrent hepatitis C infectionDiscontinuation of therapyNecro-inflammatory scoreUndetectable viral loadHepatitis C infectionResponse 6 monthsBone marrow toxicityReverse transcriptase-polymerase chain reactionTranscriptase-polymerase chain reactionHistologic benefitRecurrent HCVVirologic clearanceC infectionVirologic responseVirus recurrenceAggressive managementCombination regimenViral clearanceViral response
2002
Detection of hepatitis C virus sequences in brain tissue obtained in recurrent hepatitis C after liver transplantation
Vargas HE, Laskus T, Radkowski M, Wilkinson J, Balan V, Douglas DD, Harrison ME, Mulligan DC, Olden K, Adair D, Rakela J. Detection of hepatitis C virus sequences in brain tissue obtained in recurrent hepatitis C after liver transplantation. Liver Transplantation 2002, 8: 1014-1019. PMID: 12424714, DOI: 10.1053/jlts.2002.36393.Peer-Reviewed Original ResearchConceptsHCV RNA negative strandRecurrent hepatitis CHepatitis CBrain tissueLiver transplantationHCV replicationSevere hepatitis C recurrenceHepatitis C virus replicationCholestatic fibrosing hepatitisHepatitis C recurrenceStrand-specific TthChronic hepatitis CChronic hepatitis C.Subcortical white matterC virus replicationReverse transcriptase-polymerase chain reactionCentral nervous systemHepatitis C virus sequencesC recurrenceMultiorgan failureHepatitis C.Easy fatigabilityCerebral cortexCerebral functionPolymerase chain reaction
1995
Use of anti-hepatitis C virus seropositive organs in liver transplantation.
Mulligan DC, Goldstein RM, Crippin JS, Abouljoud MS, Levy MF, Husberg BS, Gonwa TA, Foster BR, Tillery GW, Klintmalm GB. Use of anti-hepatitis C virus seropositive organs in liver transplantation. Transplantation Proceedings 1995, 27: 1204-5. PMID: 7878850.Peer-Reviewed Original Research